English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, May 9, 2019
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
Wednesday, May 8, 2019
エーザイとUK Dementia Research Institute、認知症研究を加速する新しい博士研究員プログラムを共同で開始
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
Wednesday, May 1, 2019
エーザイ、「レンボレキサント」に関するPurdue社の権利を獲得し、提携を終結
Eisai Buys Out Purdue Rights to End Collaboration
Thursday, April 25, 2019
エーザイ、米国神経学会年次総会にてレンボレキサントおよびペランパネルに関する最新データを発表
Wednesday, April 24, 2019
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
エーザイ、「攻めのIT経営銘柄2019」に選定
Eisai Selected as Competitive ICT Strategy Company for 2019
Monday, April 8, 2019
エーザイ、新規線維芽細胞増殖因子(FGF)受容体選択的チロシンキナーゼ阻害剤「E7090」が厚生労働省の「先駆け審査指定制度」において対象品目に指定

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575